Burden of Persistent Vomiting With Cannabis Use Disorder: Report From 55,549 Hospitalizations in the United States by Patel, Rikinkumar S. et al.
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Burden of Persistent Vomiting with Cannabis Use Disorder: Report from 1 
55,549 Hospitalizations in the United States 2 
Rikinkumar S. Patel MD, MPH 3 
Department of Psychiatry, Griffin Memorial Hospital, 900 E Main St, Norman, OK 73071, USA. Email: dr.rknpatel@gmail.com 4 
Jaimin Patel MD 5 
Cleveland clinic, Florida 2950 Cleveland clinic Blvd Weston, FL 33331, USA. Email: jaimin986@gmail.com  6 
Paul Rahul Jaladi MD 7 
Rajiv Gandhi Institute of Medical Sciences, Kadapa 516002, Andhra Pradesh, India. Email: rahul3094@gmail.com  8 
Narmada N. Bhimanadham, MD9 
Department of Public Administration, Drake University, Des Moines, IA 50311, USA. Email: drneerjabn@yahoo.com 10 
Sundus Imran MD11 
Indiana University School of Medicine, Indianapolis, IN 46204, USA. Email: sunimran@iu.edu  12 
William E. Tankersley MD 13 
Department of Psychiatry, Griffin Memorial Hospital, 900 E Main St, Norman, OK 73071, USA. Email: WTankersley@odmhsas.org  14 
Corresponding author: 15 
Rikinkumar S. Patel, MD, MPH 16 
Department of Psychiatry, Griffin Memorial Hospital 17 
900 E Main St, Norman, OK 73071 (USA) 18 
Email: dr.rknpatel@gmail.com | Tel: +1 405 573 2199 19 
___________________________________________________________________
This is the author's manuscript of the article published in final edited form as:
Patel, R. S., Patel, J., Jaladi, P. R., Bhimanadham, N. N., Imran, S., & Tankersley, W. E. (2019). Burden of Persistent Vomiting 
with Cannabis Use Disorder: Report from 55,549 Hospitalizations in the United States. Psychosomatics. 
https://doi.org/10.1016/j.psym.2019.07.003
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Abstract 20 
Objective: We investigated the relationship between cannabis use disorder (CUD) and persistent 21 
vomiting (PV)-related hospitalization. Methods: Nationwide Inpatient Sample (NIS) was 22 
analyzed from 2010–2014 for patients (age 15–54) with a primary diagnosis of PV (N=55,549) 23 
and comparison was made between patients with ICD-9 classification of CUD versus non-CUD 24 
cohorts. We used logistic regression to study the odds ratio (OR) between CUD and PV. 25 
Results: The number of PV-related hospitalization with CUD had a significantly increasing 26 
trend (P<.001) with a 286% increase over five years. Higher proportion of these patients with 27 
CUD were younger (15-24 years), female and African American/Hispanic. In regression 28 
analysis, cannabis was associated with seven-fold higher odds (95% CI 6.931–7.260) of PV-29 
related hospitalization. Conclusions: This study found that CUD is independently associated 30 
with a 609% increased likelihood of PV-related hospitalization and this association persists even 31 
after adjusting for known risk factors and other substances. 32 
 33 
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1. Introduction 39 
According to the National Survey on Drug Use and Health (NSDUH), an estimated 24.6 40 
million people aged 12 or more were current users of cannabis in the US in 2016 which 41 
corresponds to 8.9% of this population group (1). From 2002 to 2014, the prevalence of cannabis 42 
use during the past month, year and almost daily had increased among adults (2). Cannabis use 43 
was higher among males and unemployed individuals (2).  44 
Severe and/or prolonged vomiting (hyperemesis) has been linked with repeated and 45 
excessive use of cannabis and has received increased attention recently (3, 4). Cannabinoid 46 
hyperemesis syndrome (CHS) is described as the episodes of cyclical nausea and vomiting which 47 
gets relieved by hot showers or bathing behavior in the chronic cannabis users (5, 6). In the 48 
previous studies, the healthcare providers have been asked to be extra vigilant for CHS in any 49 
cannabis user who presents with excessive nausea and vomiting. However, cannabinoid 50 
(dronabinol)is also FDA approved for the use of chemotherapy-induced nausea and vomiting. 51 
Therefore, it is crucial to study these contradictory and paradoxical effects of cannabis on 52 
gastrointestinal (GI) health (4).  53 
In a study by Al-Shammari et al., it was found that cannabinoid dependency and 54 
persistent vomiting (PV) increased by 17.9% during 2009 (the year when the medical 55 
cannabinoid legalization policy was implemented) as compared to the period of 1993-2008. They 56 
also found that the incidence rate of PV continued to rise significantly by about 8% in the post-57 
legalization period (2010-2014) (7). This increase in cannabis use and its adverse effects on the 58 
GI system are expected to rise primarily because of recent legalization and decriminalization of 59 
recreational cannabis use in the US (6). 60 
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In our study, we evaluated the independent association between cannabis use disorder 61 
(CUD) and PV related hospitalization, and then compared the demographic characteristics and 62 
comorbid medial/psychiatric risk factors for PV in patients with CUD and without CUD. 63 
2. Methods 64 
2.1. Data source 65 
The Healthcare Cost and Utilization Project (HCUP) collects inpatient data from about 66 
4,400 US hospitals in the form of the Nationwide Inpatient Sample (NIS) to provide 67 
epidemiological assessments of disorder-related hospitalizations (8). Diagnostic information in 68 
the NIS are documented using the International Classification of Diseases, Ninth Edition (ICD-9) 69 
codes, and clinical classification software (CCS) codes (8, 9). Individual identifiers (KEY_ID 70 
variable) are used to conceal patient identification information (10). The use of publicly available 71 
anonymized and de-identified dataset like NIS under the HCUP (8) does not require approval 72 
from an Institutional Review Board. 73 
2.2. Selection criteria 74 
We analyzed the NIS data from January 2010 to December 2014 to include emergency or 75 
non-elective based hospital admissions of patients (age 15–54 years) with a principal diagnosis 76 
for PV (ICD-9 code 536.2). Current cannabis use was identified using the ICD-9-CM codes 77 
304.30 (cannabis dependence, unspecified), 304.31 (cannabis dependence, continuous), 304.32 78 
(cannabis dependence, episodic), 305.20 (nondependent cannabis abuse, unspecified), 305.21 79 
(nondependent cannabis abuse, continuous), and 305.22 (nondependent cannabis abuse, 80 
episodic). Patients younger than 15 years of age or older than 54 years of age, and those with 81 
code for cannabis abuse/dependence, in remission were excluded to restrict our analysis to the 82 
middle 90th percentile of the cannabis users (11).  83 
2.3. Variables 84 
Various demographic variables such as age, gender, and race were examined in the 85 
analysis (10). The known possible risk factors for PV were identified by using ICD-9 and CCS 86 
diagnosis codes (Appendix A). These included medical (abdominal pain, esophageal disorders, 87 
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other GI disorders, electrolyte disorders, pregnancy or related complications, maintenance chemo 88 
or radiotherapy, renal failure and liver diseases) and psychiatric (anxiety and mood disorders) 89 
comorbidities and comorbid substance use disorders (alcohol, opioid, cocaine and amphetamine) 90 
(12). 91 
2.4. Statistical analysis 92 
We compared non-PV and PV inpatient cohorts using bivariate analysis, and the binomial 93 
logistic regression model after adjusting for demographics and risk factors (medical and 94 
psychiatric comorbidities, and other substance use disorders) measured the odds ratio (OR) for 95 
independent association between CUD and PV-related hospitalization. Next, PV inpatient cohort 96 
was grouped by co-diagnoses of CUD to compare and analyze the OR using logistic regression 97 
model for demographic characteristics and comorbidities including other substance use 98 
disorders. Statistical analyses were conducted on SPSS version 25 (IBM Corp., Armonk, NY) 99 
with significance set a priori at <.01 for all analyses. 100 
3. Results 101 
The PV (N = 31,272) and non-PV (N = 68,201,366) inpatient cohorts were analyzed in 102 
the NIS (2010 to 2014) for evaluating suspected risk factors for PV and odds of associations of 103 
various substance use disorders (SUD) with PV related hospitalization. The prevalence of PV 104 
was 0.12% (31,272 out of 68,232,638) of the total non-elective hospital admissions. 105 
When comparing with the non-PV cohort, the association of PV was higher in young 106 
inpatients (15-24 years), Whites and females. Among the medical comorbidities, abdominal pain 107 
(increased by eleven times), electrolyte disorder (increased by four times), and maintenance 108 
chemo/radiotherapy (increased by three times) were associated with higher the odds for PV 109 
hospitalizations. The predisposing psychiatric comorbidities for PV-related hospitalizations were 110 
anxiety disorder (increased by 1.7 times) and mood disorders (increased risk by 1.2 times) as 111 
shown in Table 1. As per the regression model analysis, CUD was the only significant 112 
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independent comorbid SUD associated with seven times higher odds (95% CI 6.931 – 7.260) for 113 
PV-related hospitalization after adjusting for demographics and other confounding 114 
comorbidities. 115 
PV-related hospitalizations were grouped as CUD (N = 11,554) and non-CUD (N = 116 
43,996) cohorts for further comparisons as shown in Table 2. Higher proportion of inpatients 117 
with CUD were young (54.2%, 15-24 years), female (61.8%). PV-related hospitalization was 118 
prevalent in Caucasian, and African American and Hispanic had 1.5 to 1.8 times higher risk of 119 
comorbid CUD. Patients with comorbid CUD had 1.3 times higher odds of association for 120 
electrolyte disorders and anxiety disorders compared to non-CUD patients in PV hospitalization 121 
cohort as shown in Table 2. CUD cohort patients were more likely to abuse or depend on other 122 
substances, namely cocaine (increased by 7.8 times), alcohol (increased by 1.7 times), opioid 123 
(increased by 1.6 times) and amphetamine (increased by 1.2 times).  124 
4. Discussion 125 
Using the nationwide database from the US hospitals we found that there are a significant 126 
number of inpatients with the primary discharge diagnosis of PV and comorbid CUD, and this 127 
increased from 2010 to 2014. Our results are similar to a study conducted by Bollom et al. from 128 
the national emergency department sample (NEDS) which showed that the rates of emergency 129 
visits in patients with vomiting and CUD increased from 2.3 to 13.3 per 100,000 with 68.5% 130 
increase in the inflation-adjusted associated cost (13). This increase could be due to number of 131 
reasons, namely 1. increase in the use of cannabis in the younger population; 2. increased 132 
awareness of cannabinoid hyperemesis syndrome (CHS) among healthcare providers; and 3. 133 
recent legalization and decriminalization of recreational cannabis use in the US (7). A study in 134 
Colorado was conducted during the post-cannabis legalization (2009) had similar result to our 135 
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study as they found that the prevalence of cyclic vomiting visits increased from 41 per 113,262 136 
emergency visits to 87 per 125,095, corresponding to a prevalence ratio of 1.92 (95% CI 1.33 – 137 
2.79) (14). Patients with cyclic vomiting in the post- legalization period were more likely to have 138 
cannabis use than the patients in the pre-legalization period (OR 3.59, 95% CI 1.44 – 9.00) (14). 139 
In our analysis, a higher proportion of PV-related hospitalization were seen in young 140 
adults (25-34 years, 29.7%), females (61.8%) and Whites (65.5%) which is supportive of the 141 
Colorado study (14). PV-related hospitalization with comorbid CUD was seen in young adults 142 
(15-24 years, 54.2%) as per our data analysis, and also as per a trend study conducted from 2006-143 
2013 by Bollom et al., adults (20- 29 years) had the highest rate of emergency visits for vomiting 144 
with CUD (39 per 100,000 emergency visits in 2013) (13). Though, prevalence of PV-related 145 
hospitalization with CUD was higher in Caucasians (57.2%), but African American and Hispanic 146 
had 1.5 to 1.8 times higher likelihood of comorbid CUD when compared with the non-CUD 147 
cohort. In a case series of 98 patients with CHS, 66 patients (80%) were White (15). However, 148 
the information on demographic-wise distribution of PV with CUD or CHS is not much 149 
explored. 150 
Among the medical comorbidities the odds of association for PV-related hospitalization 151 
was higher with abdominal pain, maintenance chemotherapy or radiotherapy, and esophageal or 152 
GI disorders which was not seen in PV with CUD cohort. Among psychiatric comorbidities, 153 
anxiety disorders and CUD were significantly associated with PV-related hospitalization (16). 154 
After controlling for demographic confounders, and other possible risk factors of PV, 155 
including SUD, we found that CUD increases the likelihood for PV-related hospitalization by 156 
seven times. Further, by comparing the CUD and non-CUD cohort, we found that PV inpatients 157 
with CUD had higher likelihood of co-diagnoses of cocaine (increased by 7.8 times), alcohol 158 
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(increased by 1.7 times), opioid (increased by 1.6 times) and amphetamine (increased by 1.2 159 
times) use disorders. This could be a reason for higher chances of hospitalization as a study 160 
showed that individuals with cannabis, alcohol, opioid, cocaine and amphetamine use have 161 
higher risk of emergency admission and inpatient hospitalization compared to those with only 162 
CUD (17). 163 
Many theories as per the existing literature have explained the underlying 164 
pathophysiology of CHS. CHS is caused by dysregulation of the endocannabinoid system, a 165 
group of endogenous cannabinoid receptors (CB-1 and CB-2) located in the brain, 166 
gastrointestinal tract, peripheral nervous system, and immune system of mammals. The 167 
endocannabinoid system is thought to play a role in gastrointestinal motility, appetite, 168 
nausea/vomiting, inflammation, mood, sleep, pain, and more (18). GI actions of cannabinoids are 169 
mediated chiefly by CB1 receptors. Activation of CB1 receptors result in inhibition of gastric acid 170 
secretion, lower esophageal sphincter relaxation, altered intestinal motility, visceral pain, and 171 
inflammation (19). CB1 receptor activation reduces gastric motility and results in delayed gastric 172 
emptying, which may promote nausea and vomiting (19).  In addition, it is also believed that the 173 
buildup of lipophilic THC in cerebral fat may manifest itself as toxic in some individuals which 174 
can lead to PV (13). Also, genetic variations in hepatic drug transforming enzymes in susceptible 175 
individuals may cause high levels of cannabis metabolites thereby promoting the development of 176 
vomiting (13). 177 
As, PV associated with CUD or CHS can be fatal and lead to death in some instances 178 
(20), it is important to study these conditions in detail and develop interventional strategies as 179 
cannabis cessation is the only cure for CHS (21, 22). CHS is potentially under-recognized and 180 
underdiagnosed in the emergency department. Multidisciplinary care may be necessary for 181 
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management and diagnosis. Being a diagnosis mainly based on history and physical examination, 182 
physicians cognizant of CHS who maintain a high degree of suspicion for presentation in their 183 
patient populations, can enable considerable savings and prevent unnecessary testing. CHS 184 
should be considered in the differential diagnosis of any patient presenting with persistent nausea 185 
and vomiting. In particular, the diagnosis is suggested if the patient demonstrates regular and 186 
chronic cannabis use, intractable nausea and vomiting, cyclical vomiting, relief of symptoms 187 
with hot baths, and resolution of symptoms after cannabis cessation (23). A thorough social 188 
history is needed in all cyclic vomiting patients. Higher education is needed among clinicians in 189 
order to limit repeated “exclusionary” workups and iatrogenesis. Also, as the trend toward 190 
cannabis legalization spreads, states need to create public health messages to warn cannabis users 191 
of the possibility of developing this syndrome (18). Collaborative care is a useful model for 192 
integrating behavioral (mental) health care into emergency medical settings for effective 193 
management of CHS. It aims to improve the physical and mental health of people with mental 194 
illness associated with CHS.  195 
The main limitation of this study is that due to the retrospective and administrative nature 196 
of the database the information about the dose, route of ingestion, and duration of cannabis use 197 
was not available to better explain the pathophysiology. Also, we conducted a cross-sectional 198 
study and were not able to find a causal association between CUD and PV. The other limitation 199 
of our study was that we might have under/over-estimated the number of PV-related 200 
hospitalization with CUD due to the nature of the NIS data i.e. based on ICD-9 codes recorded in 201 
the patient records for administrative and insurance/billing purpose. Also, our sample population 202 
may have affected due to change during this time period given increasing cannabis use and/or 203 
clinician awareness of CHS.  However, the main strength of our study is a large sample size of 204 
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PV-related hospitalizations that enables us to evaluate CUD as a significant risk factor in the 205 
nationally representative population. 206 
5. Conclusion 207 
The use of cannabis is on the rise in the US with legalization for both medical and 208 
recreational purposes, and subsequently, it has also been increasingly seen in the inpatient 209 
population. Our study results show that the number of patients presenting to the hospitals with 210 
complaints of nausea and vomiting associated with CUD has been increasing significantly. It is 211 
sometimes difficult and time-consuming to diagnose the causes of persistent or intractable 212 
vomiting that can lead to costly, invasive procedures. So, we would like to advise that the 213 
healthcare practitioners should have a high index of suspicion for CHS in any patient who 214 
presents to them with intractable nausea and vomiting and history of chronic cannabis 215 
consumption or co-diagnosis of CUD. The results of our study add to the growing body of 216 
evidence to suggest for the need of prospective highquality studies on cannabis consumption 217 
and health outcomes. Both the patients and healthcare practitioners will need to carefully 218 
consider the anticipated benefits in light of potentially significant health risks. 219 
 220 
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Table 1. Suspected risk factors for persistent vomiting-related ED visits 294 
Variables No PV  PV OR 95% CI P value  
Total patients 47753472 55549 - - - 
Age groups, % 
15 – 24 years 18.2 20.5 Reference 
25 – 34 years 26.7 29.7 .941 .918 – .965 < .001 
35 – 44 years 22.3 24.7 .706 .688 – .725 < .001 
45 – 54 years 32.8 25.0 .445 .433 – .457 < .001 
Sex, % 
Male 39.4 38.2 Reference 
Female 60.6 61.8 1.220 1.198 – 1.243 < .001 
Race, % 
Caucasian 56.0 65.5 Reference 
African American 21.2 21.2 .880 .860 – .899 < .001 
Hispanic 15.7 8,7 .637 .618 – .658 < .001 
Other 7.1 4.6 .757 .726 – .789 < .001 
Comorbid medical conditions, % 
Abdominal pain 2.0 27.2 11.129 10.904 – 11.358 < .001 
Esophageal 
disorders 
10.5 28.3 2.357 2.310 – 2.406 < .001 
Other GI disorders 23.1 23.8 1.636 1.601 – 1.670 < .001 
Endocrine/metabolic 
disorders 
18.1 22.0 .817 .799 – .835 < .001 
Fluid/electrolyte 
disorders 
18.5 55.1 4.374 4.295 – 4.453 < .001 
Pregnancy or related 
complications 
10.4 0 0.001 0.001 – 0.003 < .001 
Maintenance 
chemo/radio-therapy 
0 0 2.974 1.780 – 4.970 < .001 
Renal failure 4.9 4.9 1.194 1.170 – 1.219 < .001 
Liver disease 3.6 3.4 0.713 0.679 – 0.748 < .001 
Comorbid psychiatric conditions, % 
Mood disorders 15.3 28.1 1.194 1.170 – 1.219 < .001 
Anxiety disorders 10.2 24.9 1.738 1.701– 1.776 < .001 
Comorbid substance use disorder, % 
Alcohol 8.3 4.3 .346 .331 – .361 < .001 
Cannabis 3.9 20.8 7.094 6.931 – 7.260 < .001 
Opioid 3.1 4.5 .890 .852 – .929 < .001 
Amphetamine 1.0 .3 .162 .139 – .189 < .001 
Cocaine 2.4 1.0 .243 .222 – .265 < .001 
The proportion of hospitalization with/without persistent vomiting were obtained using cross tabulation and the Pearson Chi-Square (χ2) test. 295 
Significant P values ≤ .01 at 95% Confidence Interval. Odds ratio generated by binomial logistic regression model. PV: persistent vomiting; GI: 296 
gastrointestinal; OR: odds ratio; CI: confidence interval. 297 
 298 
 299 
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Table 2. Characteristics of persistent vomiting-related ED visits by cannabis use disorder. 300 
Variables CUD (–) CUD (+) OR 95% CI P value  
Total patients 43996 11554 - - - 
Age groups, % 
15 – 24 years 34.1 54.2 Reference 
25 – 34 years 65.9 45.8 .884 .835 – .936 < .001 
35 – 44 years 26.3 18.7 .455 .426 – .486 < .001 
45 – 54 years 28.3 12.7 .290 .270 – .312 < .001 
Sex, % 
Male 39.4 38.2 Reference 
Female 60.6 61.8 .422 .403 – .441 < .001 
Race, % 
Caucasian 67.6 57.2 Reference 
African American 19.7 26.9 1.844 1.746 – 1.948 < .001 
Hispanic 8.1 10.8 1.550 1.435 – 1.673 < .001 
Other 4.5 5.0 1.283 1.156 – 1.424 < .001 
Comorbid medical conditions, % 
Abdominal pain 26.9 28.1 1.018 .968 – 1.070 < .001 
Esophageal 
disorders 
27.6 30.6 1.227 1.167 – 1.290 < .001 
Other GI disorders 26.3 18.1 .723 .684 – .765 < .001 
Endocrine/metabolic 
disorders 
22.7 19.5 .942 .890 – .998 .041 
Fluid/electrolyte 
disorders 
54.2 58.2 1.249 1.193 – 1.307 < .001 
Pregnancy or related 
complications 
0 0 <.001 – .999 
Maintenance 
chemo/radio-therapy 
0 0 <.001 – .999 
Renal failure 5.6 2.0 .321 .277 – .373 < .001 
Liver disease 3.6 2.6 1.072 1.016 – 1.130 < .001 
Comorbid psychiatric conditions, % 
Mood disorders 28.4 27.0 1.072 1.016 – 1.130 < .001 
Anxiety disorders 24.0 28.1 1.311 1.243– 1.382 < .001 
Comorbid substance use disorder, % 
Alcohol 3.6 7.2 1.733 1.569 – 1.914 < .001 
Opioid 4.0 6.1 1.633 1.478 – 1.804 < .001 
Amphetamine 0.2 0.6 1.244 .866 – 1.788 .237 
Cocaine 0.4 3.3 7.788 6.377 – 9.512 < .001 
The proportion of persistent vomiting hospitalization with/without cannabis use disorder were obtained using cross tabulation and the Pearson 301 
Chi-Square (χ2) test. Significant P values ≤ .01 at 95% Confidence Interval. Odds ratio generated by binomial logistic regression model. PV: 302 
persistent vomiting; GI: gastrointestinal; CUD: cannabis use disorder; OR: odds ratio; CI: confidence interval. 303 
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